Valion Bio, Inc. (VBIO) stock
VBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.53+0.02 (+4.05%)
Close on Nov 13, 2026Market cap $2.20MP/E –Yield –
Valion Bio profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Valion Bio's profit margin for the twelve months ending Sep 30, 2025 was -1557.3%. For fiscal 2024 it was -725.0%, against -701.0% the year before.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | -725.0% | −24.0 |
| FY2023 | Dec 31, 2023 | -701.0% | −152.3 |
| FY2022 | Dec 31, 2022 | -548.7% | +127.0 |
| FY2021 | Dec 31, 2021 | -675.7% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2025 | Sep 30, 2025 | -1778.1% | −642.4 |
| Q2 FY2025 | Jun 30, 2025 | -2245.3% | −1341.1 |
| Q1 FY2025 | Mar 31, 2025 | -2145.7% | −1702.3 |
| Q4 FY2024 | Dec 31, 2024 | -820.6% | −192.3 |
| Q3 FY2024 | Sep 30, 2024 | -1135.7% | −511.6 |
| Q2 FY2024 | Jun 30, 2024 | -904.3% | +415.6 |
| Q1 FY2024 | Mar 31, 2024 | -443.4% | +119.4 |
| Q4 FY2023 | Dec 31, 2023 | -628.3% | −75.8 |
| Q3 FY2023 | Sep 30, 2023 | -624.1% | −82.4 |
| Q2 FY2023 | Jun 30, 2023 | -1319.9% | −748.3 |
| Q1 FY2023 | Mar 31, 2023 | -562.8% | −39.4 |
| Q4 FY2022 | Dec 31, 2022 | -552.5% | +404.9 |
| Q3 FY2022 | Sep 30, 2022 | -541.7% | +295.8 |
| Q2 FY2022 | Jun 30, 2022 | -571.6% | −163.4 |
| Q1 FY2022 | Mar 31, 2022 | -523.4% | −103.6 |
| Q4 FY2021 | Dec 31, 2021 | -957.3% | – |
| Q3 FY2021 | Sep 30, 2021 | -837.5% | – |
| Q2 FY2021 | Jun 30, 2021 | -408.2% | – |
| Q1 FY2021 | Mar 31, 2021 | -419.8% | – |
See a number that looks wrong?